The latest positive data from MDT’s Optimize PRO clinical study for Evolut TAVR is likely to boost the company’s business and help increase the stock’s price. Meanwhile, MDT currently has a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback